Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) saw a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 21,095,322 shares, an increase of 20.6% from the January 15th total of 17,496,604 shares. Currently, 14.2% of the company’s shares are sold short. Based on an average daily volume of 6,025,264 shares, the days-to-cover ratio is currently 3.5 days. Based on an average daily volume of 6,025,264 shares, the days-to-cover ratio is currently 3.5 days. Currently, 14.2% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

PALI has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research note on Thursday, January 22nd. B. Riley Financial started coverage on Palisade Bio in a research report on Friday, January 9th. They set a “buy” rating and a $7.00 target price for the company. Wall Street Zen downgraded shares of Palisade Bio from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Finally, Piper Sandler initiated coverage on shares of Palisade Bio in a research note on Monday, December 29th. They set an “overweight” rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Palisade Bio Stock Performance

PALI traded up $0.03 during trading on Wednesday, reaching $1.73. 1,756,917 shares of the stock were exchanged, compared to its average volume of 4,844,613. The stock has a market cap of $257.03 million, a P/E ratio of -0.81 and a beta of 1.58. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.64. The stock’s 50 day moving average price is $1.89 and its two-hundred day moving average price is $1.54.

Institutional Trading of Palisade Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers purchased a new stake in Palisade Bio in the 4th quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Palisade Bio during the 4th quarter valued at about $26,000. Atom Investors LP bought a new position in shares of Palisade Bio during the fourth quarter valued at about $33,000. Barclays PLC bought a new position in shares of Palisade Bio in the fourth quarter worth approximately $35,000. Finally, WINTON GROUP Ltd bought a new position in shares of Palisade Bio during the fourth quarter valued at about $35,000. 11.79% of the stock is owned by institutional investors.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.